SCOPUS 정보 검색 플랫폼

Ophthalmology

Volumn 120, Issue 9, 2013, Pages

Two year save outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD

(4) Wykoff, Charles C a Brown, David M a Croft, Daniel E a Wong, Tien P a

a HOUSTON METHODIST HOSPITAL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

DIABETIC RETINOPATHY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALCITRANT NEOVASCULAR AGE RELATED MACULAR DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY;

EID: 84883801815 PISSN: 01616420 EISSN: 15494713 Source Type: Journal
DOI: 10.1016/j.ophtha.2013.06.030 Document Type: Letter

Times cited : (19)

References (5)

1
- 84873325259
- Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point
- D.M. Brown, E. Chen, and A. Mariani SAVE Study Group Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point Ophthalmology 120 2013 349 354
- (2013) Ophthalmology , vol.120 , pp. 349-354
- Brown, D.M.¹ Chen, E.² Mariani, A.³ Study Group, S.⁴

2
- 84875984205
- SAVE (Super-dose Anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results
- C.C. Wykoff, D.M. Brown, and E. Chen SAVE (Super-dose Anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results Ophthalmic Surg Lasers Imaging Retina 44 2013 121 126
- (2013) Ophthalmic Surg Lasers Imaging Retina , vol.44 , pp. 121-126
- Wykoff, C.C.¹ Brown, D.M.² Chen, E.³

3
- 84877759606
- Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
- B.G. Busbee, A.C. Ho, and D.M. Brown Harbor Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
- (2013) Ophthalmology , vol.120 , pp. 1046-1056
- Busbee, B.G.¹ Ho, A.C.² Brown, D.M.³ Study Group, H.⁴

4
- 84872072339
- Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
- D.M. Brown, L. Tuomi, H. Shapiro, and PIER Study Group Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration Retina 33 2013 23 34
- (2013) Retina , vol.33 , pp. 23-34
- Brown, D.M.¹ Tuomi, L.² Shapiro, H.³ Study Group, P.⁴

5
- 84867493598
- Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)
- A.T. Fung, N. Kumar, and S.K. Vance Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) Eye (Lond) 26 2012 1181 1187
- (2012) Eye (Lond) , vol.26 , pp. 1181-1187
- Fung, A.T.¹ Kumar, N.² Vance, S.K.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.